Physician profile
Marina Gilca
NPI 1386028314
$1,700.75
in general payments reported to CMS, 2019-2025
14 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $0.83 · 2020: $56.69 · 2021: $102 · 2022: $185 · 2023: $296 · 2024: $535 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $620.72 | 2020-2025 | Vabysmo, Susvimo |
| Alimera Sciences, INC. | $264.38 | 2024 | Yutiq, Iluvien |
| Abbvie INC. | $176.00 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $144.04 | 2024-2025 | Eylea Hd |
| Astellas Pharma US INC | $135.93 | 2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $63.30 | 2023-2025 | Syfovre |
| Allergan, INC. | $58.59 | 2020-2021 | |
| Genentech, INC. | $55.16 | 2023-2025 | Susvimo, Vabysmo |
| Amgen INC. | $53.54 | 2025 | Pavblu |
| Eyepoint US, INC. | $37.08 | 2020-2023 | |
| Ani Pharmaceuticals, INC. | $35.29 | 2025 | Iluvien |
| Bausch & Lomb Americas INC. | $33.35 | 2022 | |
| Biogen, INC. | $22.54 | 2025 | Byooviz |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Gilca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.